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Abstract
In this editorial, Retrovirology's choice for best basic science "retrovirus paper of the year" and a
perspective on challenges and responsibilities facing HIV-1 and HTLV-I research are presented.
Progress
The beginning of a year provides an occasion to look back
upon progress made over the past 52 weeks. With the end
of 2004, Retrovirology concluded its first calendar year of
publishing. In actual fact, Retrovirology  launched as an
Open Access journal the final week of February 2004 and
has been publishing continuously for a little more than 10
months. Over that period, with the wonderful efforts from
my 6 very capable Associate Editors (Monsef Benkirane,
Ben Berkhout, Masa Fujii, Mike Lairmore, Andrew Lever,
and Mark Wainberg), the journal has thrived.
The goal that we set for Retrovirology is to provide a visible
forum for retrovirologists so that their works can be read
by all in a free and openly accessible manner. What this
means is that if you are a human immunodeficiency virus
(HIV)-researcher and you had published a paper in Retro-
virology, a graduate student in Sri Lanka updating his/her
research protocol, an AIDS activist in South Africa looking
for the latest information, and even your long-lost high
school sweetheart wondering what you have been doing
all these years, can all find your work (i.e. through a sim-
ple Google or PubMed search) and read your most recent
findings. Perhaps more relevant to the enterprise of scien-
tific communication is that numerous academic peers in
Eastern Europe, Asia, South America, Africa and elsewhere
do not have funds which would permit them to read Cell,
Science  or  Nature. Hence, while some can read your
research in Cell, Science, or Nature, all colleagues, rich or
poor alike, can read your Retrovirology paper.
Are they reading Retrovirology? You bet! Our monitored
statistics tell us that in 2004, the most highly accessed
review article [1] published in Retrovirology was read by
over 3,500 individuals while a comparably popular origi-
nal research article [2] was read more than 2,400 times.
Readers also read Retrovirology articles with great immedi-
acy. Thus, a recent paper by Rana and colleagues [3]
appeared in Retrovirology on December 27th, 2004; and
already by December 31st, 2004, a short 4 days later, that
study had been read 389 times. Just as readers are quick to
read our papers, I am equally pleased by our unmatched
speed in publishing authors'works. In 2004, based on all
papers we published in Retrovirology, the time from sub-
mission to publication averaged 40 days. From my per-
sonal experience of publishing in other virological
journals, this duration is 3 to 4 times faster than our best
competitors.
Different journals/magazines recognize "Molecule of the
Year", "Breakthrough of the Year", or even "Person of the
Year". With this editorial, Retrovirology  will initiate the
annual recognition of the best basic science "retrovirus
paper of the year". The Associate Editors and I decided
that in 2004, the best basic science retrovirus paper was
the work from Joseph Sodroski and colleagues describing
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the HIV-1 restrictive property of the tripartite motif 5
(TRIM5) protein [4]. Thus, these researchers characterized
in primates a restriction factor, similar to the Friend virus
susceptibility factor-1 (Fv1) in mice, which counters the
ability of infecting retrovirus to establish a proviral form
in target cells. In coming years, I anticipate that Retrovirol-
ogy Editors will find it fitting to recognize a Retrovirology
paper as the "best basic science retrovirus paper" of the
preceding year.
Challenges and responsibilities
I explain to my postdoctoral fellows that challenges are
those issues which you think others should solve, while
responsibilities are items that you think you should
tackle. As a retrovirologist depending on how you regard
yourself, pressing problems are either others' challenges
or your responsibilities. I study two retroviruses, HIV-1
and human T-cell leukaemia virus type 1 (HTLV-I). The
start of a new year offers me a chance to review briefly my
personal bias on the important research question that
confronts HIV-1 and HTLV-I, respectively.
For HIV-1, the "holy grail" remains the development of an
effective vaccine against the virus. As we enter 2005, mor-
tality from AIDS is staggering. It is estimated that in 2004,
3.5 million individuals perished worldwide from AIDS; or
nearly 10,000 AIDS deaths each day. We can view this
number in another way. The recent tsunami in South Asia
is estimated to have caused 150,000 fatalities. AIDS in
2004 is then the equivalent of 23 tsunamis. Imagine,
unrelentingly tsunami-like casualties every fortnight from
people dying from HIV-1! While it is laudable that the
World Health Organization has a goal to treat three mil-
lion HIV-1 positive individuals globally using anti-retrovi-
ral (ARV) medicine over the next five years, that approach
will unlikely address the full magnitude of the AIDS prob-
lem, especially in developing nations. On the other hand,
100 million infants (even those in remote regions of the
world) receive basic vaccinations each year. This fact sug-
gests that when an AIDS vaccine does become available,
that vaccine could be logistically and practically effective.
Separately, statistics from the World Cancer Report for the
year 2000 show that 5.3 million men and 4.7 million
women developed malignancy, and altogether 6.2 mil-
lion persons died from cancer worldwide. The American
Cancer Society estimates that approximately 553,000
individuals succumb to cancer in the United States each
year. I see HTLV-I, the etiological agent for adult T-cell leu-
kaemia (ATL), as perhaps the best retroviral system for ret-
rovirologists to study human cancer. Substantive progress
has indeed been made in our understanding as to how
HTLV-I transforms cells in tissue culture [5]. What
remains needed is the development of a good non-human
primate model to investigate the genesis of adult T-cell
leukaemia by the virus in vivo.
Opportunities and limitations at mid-career
I first started studying viruses in the fall of 1977 at age 19
as a MD-PhD student at the Johns Hopkins school of
medicine. For me personally, 2004 marked over a quarter-
century of virus-research. At age 46, the unbridled youth-
ful optimism of 19 is now tempered by realizations of
physical and career limitations (i.e. some very interesting
research problems are going to take longer to resolve than
the remaining span of my scientific and physical
endeavor). Nonetheless, I am optimistic and hopeful that,
despite enormous odds, the opportunity to see a success-
ful AIDS vaccine will come before I leave retrovirology
research in 20 or some years. Regarding Retrovirology, I am
also optimistic that I started this project at an age that pro-
vides ample time to develop this journal into a premier
research forum.
Let me conclude this writing by thanking all authors,
reviewers, Editorial board members, and our wonderful
staff at Biomed Central who have contributed to Retrovi-
rology's progress in our first year.
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